2331 - 2340 of 7942 Results
Title
Year
-
RESTRICTEDTitle: The Human Tic Detector: An automatic approach to tic characterization using wearable sensorsJournal Name: Clinical NeurophysiologyPublisher: Elsevier BVVol: 134Issue #:Start Page: 102End Page: 110Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.clinph.2021.10.017Citation Count: 9
- White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer's disease and frontotemporal dementia2021OPENTitle: White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer's disease and frontotemporal dementiaJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 111Issue #:Start Page: 54End Page: 63Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2021.11.007Best OA location URL: http://escholarship.mcgill.ca/downloads/ns064b900Citation Count: 40
- Atlas of RNA editing events affecting protein expression in aged and Alzheimer’s disease human brain tissue2021OPENTitle: Atlas of RNA editing events affecting protein expression in aged and Alzheimer’s disease human brain tissueJournal Name: Nature CommunicationsPublisher: Springer Science and Business Media LLCVol: 12Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41467-021-27204-9Best OA location URL: https://www.nature.com/articles/s41467-021-27204-9.pdfCitation Count: 32
-
OPENTitle: Different rates of cognitive decline in autosomal dominant and late‐onset Alzheimer diseaseJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 18Issue #: 10Start Page: 1754End Page: 1764Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/alz.12505Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160203Citation Count: 6
-
RESTRICTEDTitle: For Some Neurologists, COVID-19 Has Prompted an ‘Existential Crisis’Journal Name: Neurology TodayPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 21Issue #: 23Start Page: 1,22End Page: 25Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1097/01.nt.0000805196.94665.beCitation Count: 0
-
RESTRICTEDTitle: How to Increase Diverse Representation in Parkinson's Disease TrialsJournal Name: Neurology TodayPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 21Issue #: 23Start Page: 20End Page: 22Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1097/01.nt.0000805216.68841.48Citation Count: 0
- Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson’s Disease: Focus on Neuroinflammation2021OPENTitle: Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson’s Disease: Focus on NeuroinflammationJournal Name: Molecular NeurobiologyPublisher: Springer Science and Business Media LLCVol: 59Issue #: 2Start Page: 1140End Page: 1150Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1007/s12035-021-02625-1Citation Count: 10
-
RESTRICTEDTitle: MS Study That Spans Decades Indicates Patients Benefit from Early Diagnosis and TreatmentJournal Name: Neurology TodayPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 21Issue #: 23Start Page: 1,17End Page: 20Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1097/01.nt.0000805208.98399.94Citation Count: 0
-
RESTRICTEDTitle: Multiplexed Profiling of Extracellular Vesicles for Biomarker DevelopmentJournal Name: Nano-Micro LettersPublisher: Springer Science and Business Media LLCVol: 14Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1007/s40820-021-00753-wBest OA location URL: https://link.springer.com/content/pdf/10.1007/s40820-021-00753-w.pdfCitation Count: 42
- Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis2021OPENTitle: Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia GravisJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 98Issue #: 4Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/wnl.0000000000013121Best OA location URL: https://n.neurology.org/content/neurology/98/4/e376.full.pdfCitation Count: 65